Ensysce Biosciences Announces Engagement of Alacrita Consulting
- None.
- None.
Engagement to aid expansion of the use of TAAP and MPAR® as well as the rapid development and commercialization of Ensysce's next generation opioids
SAN DIEGO, CA / ACCESSWIRE / July 26, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has engaged Alacrita Consulting ("Alacrita"), a pharma and biotech consulting firm with extensive subject-matter expertise for the purpose of exploring partnering and licensing opportunities for its TAPP and MPAR® platforms and products.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce commented, "We are pleased to be working with Alacrita and its team of highly experienced experts to explore opportunities to aid our growth and development." Dr. Kirkpatrick added, "Our goal is to rapidly develop both PF614 and PF614-MPAR, as well as expand the use of our TAAP and MPAR® technologies, and we believe Alacrita's team is the perfect group to aid us in achieving this goal."
About Alacrita
Founded in 2009, Alacrita is an expertise-based consulting firm serving biotech and pharma companies, academic institutions and healthcare investors, across a range of disciplines, therapeutic areas and technologies. Its core team leverages a consulting network of 250+ functional specialists, all with at least 20 years of pharmaceutical industry experience, allowing it to offer a versatile combination of depth and breadth in expertise that is unrivaled in the industry and that can be precisely tailored to the needs of each client. The firm provides consulting support on a range of R&D and business issues.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is in the process of developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/770343/Ensysce-Biosciences-Announces-Engagement-of-Alacrita-Consulting
FAQ
What is Ensysce Biosciences, Inc. (NASDAQ:ENSC) announcing?
What are the goals of this engagement?
Who is Alacrita Consulting?
Who commented on the engagement?
What is the expertise of Alacrita's team?
